Altimmune ALT
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Altimmune (ALT)
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Key Insights
Critical company metrics and information
Latest Closing Price
$5.57Market Cap
$428.97 MillionPrice-Earnings Ratio
-3.55Total Outstanding Shares
77.01 Million SharesTotal Employees
59Dividend
No dividendIPO Date
October 6, 2005SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQType
Common StockHeadquarters
910 clopper road, Gaithersburg, MD, 20878Homepage
https://www.altimmune.com
Historical Stock Splits
If you bought 15,000 shares of ALT before July 25, 2007, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| September 14, 2018 | 1-for-30 (Reverse Split) |
| May 4, 2017 | 1-for-10 (Reverse Split) |
| July 25, 2007 | 1-for-50 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities | $-49.98 Million |
| Net Cash Flow | $-55.38 Million |
| Net Cash Flow From Financing Activities | $72.71 Million |
| Net Cash Flow From Operating Activities | $-78.12 Million |
| Net Cash Flow From Investing Activities, Continuing | $-49.98 Million |
| Net Cash Flow From Operating Activities, Continuing | $-78.12 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Diluted Earnings Per Share | $-1.57 |
| Net Income/Loss Available To Common Stockholders, Basic | $-103.52 Million |
| Income/Loss From Continuing Operations After Tax | $-103.52 Million |
| Operating Income/Loss | $-111.93 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Revenues | $52,000 |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $279,000 |
| Comprehensive Income/Loss Attributable To Parent | $-103.24 Million |
| Comprehensive Income/Loss | $-103.24 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Fixed Assets | $446,000 |
| Wages | $2.31 Million |
| Equity | $133.38 Million |
| Accounts Payable | $1.13 Million |
| Liabilities | $14.49 Million |
| Assets | $147.86 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about ALT from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.